Ghazaleh Bankefors: Reconnecting Across Borders and Decades at EHA 2026
Ghazaleh Bankefors, Global Systems Specialst at Thermo Fisher Scientific, shared a post on LinkedIn:
“One of the nicest surprises this year was reconnecting with a childhood friend after 25 years.
We grew up in the same country, but life took us in very different directions.
About 15 years ago, she moved to Germany and I moved to Sweden — and over the years, we built our lives far apart.
Today, she invited me to EHA 2026 in Stockholm, and after all this time, we finally met again in person.
Seeing each other after so many years felt as if no time had passed at all.
We shared old memories, caught up on where life has taken us, and reflected on how differently our journeys unfolded.
As an extra bonus, it was wonderful to see the exciting work presented by Thermo Fisher Scientific and to learn more about the latest advances in hemato-oncology and Rapid NGS.
And I have to say — I’m really proud of you. Dr. Niloufar Monhasery.”
Stay updated with Hemostasis Today.
-
Jun 13, 2026, 15:39Ritu Verma: Recognizing Deep Vein Thrombosis Before Complications Arise
-
Jun 13, 2026, 15:09Akshat Jain: Does Mitapivat Translate to Clinical Benefit in SCD?
-
Jun 13, 2026, 14:58Olga Benítez Hidalgo: New Evidence on Marstacimab in Hemophilia Care
-
Jun 13, 2026, 14:52Sophie Georgin-Lavialle: First ERN-RITA Recommendations on USAID
-
Jun 13, 2026, 14:48Andrew Jackson: Personalized Approaches to Catheter-Related Thrombosis Prevention
-
Jun 13, 2026, 14:41Tom Langenaeken: Targeting Factor XI in Mechanical Heart Valve Thrombosis
-
Jun 13, 2026, 14:36Heghine Khachatryan: Pregnancy, Thrombosis, and Aspirin – Who Really Needs Prophylaxis?
-
Jun 13, 2026, 14:24Thomas Stauch: ITP Therapeutics Enter a New Era of Targeted Treatment
-
Jun 13, 2026, 14:07Long-Term Outcomes and Future Directions in Hemophilia Gene Therapy: Insights from EHA 2026